Description
Specifications
| Form | Lyophilized powder, single vial |
| Contents | GLP-3(R) 10 mg · Eloralintide 2.5 mg |
| Made in | USA |
| Testing | Third-party identity and purity, every lot |
| GLP-3(R) | C₂₂₁H₃₄₂N₄₆O₆₈ · MW 4731.3 · CAS 2381089-83-2 |
| Eloralintide | 37-amino-acid modified polypeptide with a fatty diacid side chain (LY3841136) |
How Is This Blend Studied?
This blend pairs two peptides that act on separate metabolic signaling pathways. GLP-3(R) is researched as a triple receptor agonist acting on GIP, GLP-1 and glucagon receptors at once. Eloralintide is a long-acting, selective agonist of the amylin type 1 receptor. Amylin agonists act on calcitonin-family receptors rather than incretin receptors, so the combination is used in preclinical research comparing and combining incretin and amylin pathway signaling.
Storage
Store the sealed vial at −20 °C for long-term storage, or 2–8 °C short-term, away from light. Once reconstituted in the lab, keep at 2–8 °C and don’t freeze it. See our storage guide.
FAQ
Are these available on their own?
Yes. See GLP-3(R) and Eloralintide, and GLP research compounds compared for how they fit together.
Is a Certificate of Analysis available?
Yes. Every lot is third-party tested, and the current lot’s COA is posted on this page.
Do you provide use or dosing guidance?
No. This product is sold strictly for laboratory research, and orders indicating human or animal use are cancelled.
For laboratory research use only. Not for human consumption.
